Additionally, GCS inhibitors, such as eliglustat, are a clinically available treatment option for Gaucher disease, a rare inherited metabolic disorder in which deficiency of the enzyme glucocerebrosidase results in lysosomal accumulation of glucocerebrosides45. Here, UGCG is linked to Gaucher disease.